Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
Healthcare
$8.27 +3.05%
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
52W Low $9.85High $16.76
Volume 0.13M
Average 0.11M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$23.59M
FY 2025 · Annual
Investing Cash Flow
-$18,000.00
FY 2025 · Annual
Financing Cash Flow
$70.48M
FY 2025 · Annual
+3.6% YoYCash Flow Statement
USD
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (13.88M) | (18.21M) | (19.56M) | (21.75M) | (37.92M) |
| Depreciation & Amortization | 424K | 392K | 381K | 343K | 396K |
| Deferred Income Tax | 0 | 0 | (714K) | 0 | 0 |
| Stock-Based Compensation | 634K | 870K | 452K | 830K | 17.43M |
| Change in Working Capital | 8K | 1.04M | 714K | 1.17M | (2.73M) |
| Accounts Receivables | 28K | 1K | (50K) | (176K) | 197K |
| Inventory | (83K) | (1.09M) | (1.31M) | 0 | 0 |
| Accounts Payables | 55K | 1.09M | 1.36M | 0 | (2.38M) |
| Other Working Capital | 8K | 1.04M | 714K | 1.35M | (548K) |
| Other Non-Cash Items | (16K) | 10K | 717K | 1K | (764K) |
| Operating Cash Flow | (12.83M) | (15.9M) | (18.01M) | (19.4M) | (23.59M) |
| Capital Expenditures | (221K) | (13K) | (1K) | (179K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (221K) | (13K) | (1K) | (179K) | (18K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 25.75M | 0 | 17.88M | 70.88M | 70.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.23M) | 0 | (1.87M) | (2.85M) | 0 |
| Financing Cash Flow | 22.52M | 0 | 16.02M | 68.03M | 70.49M |
| Effect of Forex Changes | 499K | 204K | 412K | (8K) | 49K |
| Net Change in Cash | 9.97M | (15.71M) | (1.59M) | 48.44M | 46.93M |
| Free Cash Flow | (13.05M) | (15.91M) | (18.01M) | (19.58M) | (23.61M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$37.9M
+ D&A$396.0K
+ Stock-Based Comp$17.4M
+ Deferred Tax$0
- Working Capital-$2.7M
- Other Non-Cash-$764.0K
= Operating Cash Flow-$23.6M
- Capex-$18.0K
= Free Cash Flow-$23.6M
Analysis
FY2025 free cash flow is -$23.6M. FCF conversion is 62.3% of net income. Operating cash flow was -$23.6M, with capex of -$18.0K. The largest bridge item is Stock-Based Comp at $17.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Oct 28, 2026 | |
| DEFA14A | DEFA14A filing | Oct 20, 2026 | |
| DEF 14A | DEF 14A filing | Oct 20, 2026 |
Does BNTC generate free cash flow?
Benitec Biopharma Inc. (BNTC) generated -$23.61M of free cash flow in fiscal 2025.
How much operating cash flow does BNTC produce?
Operating cash flow was -$23.59M, before capital expenditures of $18,000.00.
Continue the stock analysis
Jump to another research area for this company.